105P Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected non-small cell lung cancer

Abstract

Background: Hypoxia in the center of large tumor directly leads to radiation resistance. Concurrently, heat loss results in incomplete ablation oflarge tumors abutting airways or blood vessels. The combining stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) for non-small cell lung cancer (NSCLC) treatment could overcome respective shortcoming. Methods: In this study, we report our experience with combined SBRT and RFA in 27 medically inoperable patients with biopsy-proven T2aN0M0 NSCLC. Patients were treated with SBRT to a dose of 50 Gy followed by CTguided RFA within 7 days. Results: There were no treatment-related deaths. At a mean follow-up period of 29.6 months (range, 3 to 56 months), 15 patients (55.6%) died, with 1-year, 2-year, and 3-year cumulative survival rates of 77.8%, 63.0% and 48.1%, respectively. Threeof the deaths were cancer related. Four (14.8%) and five (18.5%) patients had local and distant recurrence, respectively. Conclusions: We concluded that SBRT followed by RFA appears effective for centrally located NSCLC. Survival rates appear to be better than with SBRT or RFA alone. Interactions between the two modalities warrants deeper investigation. Legal entity responsible for the study: N/A Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.